Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.80 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | RECQL | P46063 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | APEX1 | P27695 | 3/20 | 0.59 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685824 | 0.96 | EPHX2 (0.85) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL6689193 | 0.91 | EPHX2 (0.84) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL6072546 | 0.89 | EPHX2 (1.00) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL15452189 | 0.88 | EPHX2 (0.70) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL10307570 | 0.86 | EPHX2 (0.76) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL10307571 | 0.84 | EPHX2 (0.76) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL23442030 | 0.84 | EPHX2 (0.88) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL10307572 | 0.83 | ABCB1 (0.64) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL23442126 | 0.81 | EPHX2 (0.88) | EPHX2POLBKDM4EMAPTRECQL | |
| SCHEMBL15449134 | 0.81 | ABCB1 (0.65) | EPHX2POLBKDM4EMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214688-B1 | MANAGEMENT AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CSIR (ZA) | 2018-09-05 | — | — | EP | disclosed |
| US-9061023-B2 | Management and treatment of benign prostatic hyperplasia | CSIR (ZA) | 2015-06-23 | — | — | US | disclosed |
| US-20100316748-A1 | MANAGEMENT AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CSIR (ZA) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316748-A1 | MANAGEMENT AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | BPHL, CYP17A1, CYP46A1 | EPHX2 2030/4885POLB 1655/4885KDM4E 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.